Scrip
US and EU reviewing risks of Abbott's sibutramine
23 November 2009
Nancy Faigen
Both the
US FDA and the EU's
CHMP are reviewing "preliminary data" suggesting that patients taking
Abbott Laboratories' diet drug Meridia (sibutramine monohydrate) have a higher risk of cardiovascular problems than patients taking placebo.
The reviews were initiated on the basis of preliminary...
Please Login to read the full article.
23 November 2009
Nancy Faigen
The reviews were initiated on the basis of preliminary...
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
FEATURES
- Light Sciences Oncology - making light-activated drug therapy a commercial reality
- Face-to-face: Evotec CEO tells of turnaround
EVENTS
10 February 2010
London, UK
11 February 2010
London, UK
23 February 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
